Brooklyn-based biotechnology company Cresilon announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its groundbreaking product TRAUMAGEL.
This gel-like product, created on the basis of herbal ingredients, is intended for temporary external use and effectively stops moderate and severe bleeding.
Developed using Cresilon’s patented hydrogel technology, TRAUMAGEL can quickly stop life-threatening bleeding, making it indispensable for emergency medicine.
The company plans to launch the product strategically in the U.S. in late 2024, targeting military, emergency services, and healthcare organizations.
Source: Ferra
I am a professional journalist and content creator with extensive experience writing for news websites. I currently work as an author at Gadget Onus, where I specialize in covering hot news topics. My written pieces have been published on some of the biggest media outlets around the world, including The Guardian and BBC News.
